| Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers (NCT05296564) | Hadassah Medical Organization | 2022-04-01 |
| A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma (NCT05220124) | Tianjin Medical University Second Hospital | 2022-01-05 |
| Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib (NCT05052372) | xCures | 2021-11-21 |
| Milademetan in Advanced/Metastatic Solid Tumors (NCT05012397) | Rain Oncology Inc | 2021-11-01 |
| Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors (NCT04985604) | Day One Biopharmaceuticals, Inc. | 2021-07-15 |
| En Bloc TURBT With Collins Loop vs Conventional TURBT (NCT05027412) | Hospital Universitario de Fuenlabrada | 2021-04-01 |
| A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial (NCT04216290) | National Cancer Institute (NCI) | 2021-03-17 |
| Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) (NCT04574960) | University Health Network, Toronto | 2021-02-08 |
| Safety Analysis and Oncological Outcomes in HoLERT vs TURBT (NCT05833997) | Instituto do Cancer do Estado de São Paulo | 2020-12-10 |
| Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma (NCT04570410) | The First Affiliated Hospital with Nanjing Medical University | 2020-12-01 |
| A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies (NCT04440943) | Celldex Therapeutics | 2020-08-04 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma (NCT04200963) | Ikena Oncology | 2019-12-18 |
| Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy (NCT04129606) | Abdelwahab Hashem | 2019-07-01 |
| Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (NCT03775265) | National Cancer Institute (NCI) | 2019-06-03 |
| Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer (NCT03912818) | Stanford University | 2019-04-10 |
| Can VI-RADS/ADC Accurately Stage Bladder Cancer?? (NCT04167631) | Mansoura University | 2019-01-01 |
| Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer (NCT03601455) | Jonsson Comprehensive Cancer Center | 2018-10-26 |
| Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer (NCT03473730) | M.D. Anderson Cancer Center | 2018-05-29 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Celldex Therapeutics | 2017-12-01 |
| A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival (NCT03266900) | University Health Network, Toronto | 2017-11-16 |
| Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC (NCT03138824) | Mansoura University | 2017-05-15 |
| Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma (NCT03113266) | Shanghai Junshi Bioscience Co., Ltd. | 2017-04-06 |
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers (NCT02989064) | Adaptimmune | 2016-10-01 |
| Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy (NCT03039413) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2016-09-28 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (NCT02496208) | National Cancer Institute (NCI) | 2015-07-22 |
| The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma (NCT01968928) | National Taiwan University Hospital | 2014-01-01 |
| Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK. (NCT06167356) | IRCCS San Raffaele | 2013-11-27 |
| Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy (NCT06170177) | IRCCS San Raffaele | 2013-02-04 |
| Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy (NCT00072137) | National Cancer Institute (NCI) | 2003-10-01 |